Skip to content

The Best Dosage and Timing of Polyethylene Glycol for Bowel Preparation Before Capsule Endoscopy

The Best Dosage and Timing of PEG for Bowel Preparation Before Capsule Endoscopy a Prospective, Single-Blind, Randomized, Multi-center Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02486536
Enrollment
410
Registered
2015-07-01
Start date
2015-07-31
Completion date
2017-06-30
Last updated
2017-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small Bowel Disease

Keywords

capsule endoscopy, polyethylene glycol, bowel preparation solutions

Brief summary

The aim of this study is to evaluate the ideal dose of PEG and timing of bowel preparation in patients referred for CE examination.

Interventions

DRUGpolyethylene glycol
DEVICEcapsule endoscopy

Sponsors

Huashan Hospital
CollaboratorOTHER
Shanghai East Hospital
CollaboratorOTHER
Shanghai Tong Ren Hospital
CollaboratorOTHER
Zhizheng Ge
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged between 18 and 75 years and referred to capsule endoscopy because of suspected small-bowel disease are prospectively eligible for entry into the study.

Exclusion criteria

* Age \< 18 or \> 75 years * Known or suspected GI stricture or fistula * A history of GI tract resection * Swallowing disorders * Intensive therapy with fasting and parenteral nutrition;with a disease that may reduce movement of the GI tract, such as diabetes mellitus * Medications that could affect gastrointestinal movement within one week * Implanted with a medical electronic device * Active inflammatory bowel disease, toxic megacolon, toxic colitis * Severe pulmonary, cardiac, renal, or hepatic disease * Uncontrolled hypertension (systolic blood pressure\>170 mm Hg, diastolic blood pressure\>100 mm Hg); * Disturbance of electrolytes * Pregnancy or lactation * Patients inability to provide written voluntary informed consent * Participation in another clinical study

Design outcomes

Primary

MeasureTime frameDescription
the quality of visualization of the small bowelone week after CE procedureThe image quality was evaluated only in cases in which the capsule reached the cecum within the examination period. All CE images will be assessed at low speed (10 frames/s) under the AutoView mode of the RAPID workstation (Given Imaging). The intestinal mucosa is defined as clean if, less than 25% of the mucosal surface was covered by dark liquid, bubbles or debris. Using a timer, the investigators record the exact time period during which the small intestinal mucosa was clean. The definition of excellent is at least 90% of the overall small bowel mucosa is clean (the sum of clean time /total small bowel transit time\>90%). And the definition of good is at least 80% of the overall small bowel mucosa is clean. We considered that excellent or good preparation is adequate to make an accurate diagnosis.

Secondary

MeasureTime frameDescription
patient acceptabilityday of CE procedureA visual analogical scale (VAS) is used to evaluate the degree of patients' discomfort. The numerical scale between 0 and 10, with 0 being no burden at all and 10 indicating an intolerable procedure. The questionnaire provide information about whether they experienced nausea, bloating, or any discomfort during the bowel preparation, difficulty to complete the preparation, their willingness to repeat the same preparation in the future (yes or no)and did it affect their daily activity and nocturnal rest.
diagnostic rateone year

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 20, 2026